The compensation order for J&J’s faulty hip implants is a major breakthrough for suffering patients The American healthcare giant, Johnson & Johnson (J&J), has reportedly been commanded by India’s …
The new joint venture will be dedicated towards the research and development of cannabinoid formulations for treating ophthalmic disorders and address significant unmet medical needs in the market A …
The feature will initially be available on Samsung’s Android Pie OS supporting smartphones and will launch in 10 markets globally. Samsung’s health tracking app, Samsung Health is reportedly collaborating …
Pharmaceutical giant Eli Lilly has hit the headlines after company’s Chairman and CEO Dave Ricks publicized the launch of an affordable version of Humalog, its rapid-acting insulin brand. Eli …
The latest results indicate a promising risk-benefit profile in all pemphigus patients Principia Biopharma now intends to confirm these results through the current Phase 3 PEGASUS study Principia Biopharma …
In accordance with the preliminary results, the company looks forward to a Phase 2 trial by this year’s third quarter, in kids with achondroplasia. Ascendis Pharma A/S, the Denmark-based, …
CureVac’s vaccine platform has the potential to improve CEPI’s ability to respond to the emerging Disease X, claims CEPI CEO. In a move to defeat the next pandemic, the …
Lynparza was the first PARP drug to reach the market after it was approved for ovarian cancer in U.S. Leading multinational pharmaceutical and biopharmaceutical firm, AstraZeneca Plc., has recently …
The U.S. Food & Drug Administration (FDA) has reportedly approved TAS-102 (trifluridine/tipiracil; Lonsurf, Taiho Oncology) for the treatment of adult patients afflicted with metastatic GEJ (gastroesophageal junction) adenocarcinoma. Reportedly, …
Eyenovia, Inc., has reportedly declared attaining positive results from its second MicroStat Phase III study, known as MIST-2. If reports are to be believed this study evaluated the efficacy …
